



GLYCATION OF BETA AMYLOIDS AND THEIR CONTRIBUTION TO INSULIN 
RESISTANCE IN TYPE 2 DIABETES MELLITUS 
 
by 
Eric Kyunam Kim 
 
A thesis submitted to Johns Hopkins University in conformity with the requirements for the 
 











 Type 2 Diabetes Mellitus (T2DM) is metabolic disorder that afflicts 200,000 Americans 
per year and a total of 463 million people globally. Due to significant dietary changes that 
increase intake of fats and sugars, 9.5% of Americans over 18 years old begin to develop pre-
diabetes  old and left untreated should expect to develop T2DM within 5 years. Although 
researchers have been able to link diet, genetic factors and epigenetic factors to T2DM, the 
mechanism through which Type 2 Diabetes develops remains elusive. Diabetic patients 
experience a wide range of symptoms, the most significant of which are impaired insulin action, 
hyperlipidemia, and chronic inflammation. Recently researchers have observed that beta amyloid 
accumulation can cause insulin resistance both directly and indirectly. Beta amyloids can bind to 
cell surface and cause chronic inflammation by over-stimulating the JAK/STAT pathway as well 
as cause free fatty acid (FFA) accumulation within cells through CD36 activation caused by 
Ca2+ influx.  Glycation, the non-enzymatic addition of glucose molecules to beta amyloids, also 
can contribute significantly to the accumulation of beta amyloids in the body. Beta amyloids in 
high glucose environments appear to exhibit reduced clearance for in vivo models similar to 
those of glycosylated beta amyloids due to London and Sweden mutation exhibiting patients. 
This information suggests that glycated beta amyloids show decreased elimination compared to 
non-glycated beta amyloids.  In this paper, we explore the potential accumulation of beta 
amyloids and glycated beta amyloids through a multi-compartment model sensitivity analysis 
that adjusts the glycation rate constant and perfusion of glucose between the intestines and 
visceral adipose tissue. From our results we conclude that the glycation reaction rate of beta 
amyloids has a greater variability on the overall accumulation of glycated beta amyloids than the 
concentration of glucose in the organ compartments. This variability is dependent on whether the 
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patient consumes high glycemic index (GI) meals or low GI meals.  However, it is unknown if 
such small changes to blood volume glucose concentrations will result in insulin resistance 
potential. Future development of the model should implement the influx of beta amyloids into 
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Abbreviations and Notations 
 
AD – Alzheimer’s disease: A neurodegenerative disease that worsens cognitive and physical 
functions over time. [18] 
AGEs – Advanced Glycation End Products: Highly processed glycated molecules which 
functions are inhibited and can accumulate in the body. (Most tissues and blood) [37] 
APP – Amyloid Precursor Protein: A membrane protein which when cleaved creates beta 
amyloid proteins. (Most Tissues) [29] 
CD36 – Cluster of Differentiation 36: A membrane protein which facilitates the intracellular 
influx of free fatty acids from the bloodstream. (Primarily adipocytes, hepatocytes, and 
myocytes) [11] 
C-Jun – C-Jun: A downstream protein which drives the pro-inflammatory process within a cell. 
(Most cells) [14] 
EGFR – Epidermal Growth Factor Receptor: A transmembrane protein which binds to epidermal 
growth factor family proteins. (Most cells) [21] 
FFAs – Free Fatty Acids: Non-esterified fatty acids that are bound to a transport protein which 
circulate in the plasma. (Bloodstream) [9] 
GI – Glycemic Index: A score associated with food which signifies the potential rise of blood 
glucose levels two hours after eating a meal. 
GLUT4 – Glucose Transporter Type 4: An insulin-regulated protein which facilitates the 
absorption of glucose into a cell. (Primarily adipocytes, hepatocytes, and myocytes) [2] 
IKK – IκB Kinase: An enzyme complex involved in the activation of nf-κB transcription factors 
for pro-inflammatory responses. (Most cells) [14] 
IRS – Insulin Receptor Substrate: An insulin-dependent signaling protein which activates the 
insulin action within a cell. (Primarily adipocytes, hepatocytes, and myocytes) [2] 
JAK – Janus Kinase: A family of pro-inflammatory signaling proteins in the JAK/STAT 
pathway. (Most Cells) [13] 
JNK – c-Jun N-terminal Kinases: A pro-inflammatory signaling protein in the MAPK pathway. 
(Most Cells) [14] 
KO – Knock-Out: A technique which inactivates genetic expression of a specific gene. [12] 
krxn – Glycation reaction rate: The glycation reaction rate of a glucose molecule and a non-
glycated beta amyloid protein. 
MAPK – Mitogen-Activated Protein Kinase: A pro-inflammatory signaling pathway that involve 
responses of inflammatory cytokines. (Most Cells) [13] 
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NEP – Neprilysin: A zinc-dependent metalloprotease which can degrade many proteins 
including beta amyloid peptides. (Most tissue and blood) [33] 
nf-κB – nuclear factor kappa-light-chain-enhancer of activated B cells: A protein complex which 
controls cellular functions including cytokine expression for inflammation. (Most Cells) [13] 
PI3K - Phosphoinositide 3-kinase: A family of enzymes responsible for activating PIP2 to PIP3 
for many cell functions including insulin signaling. (Most Cells) [2] 
PIP2 - Phosphatidylinositol 4,5-biphsophate: Dephosphorylated phospholipid of PIP3 which is 
phosphorylated by PI3K. (Most Cells) [2] 
PIP3 - Phosphatidylinositol 3,4,5-triphsophate: Phosphorylated phospholipid which activates 
downstream proteins such as protein kinase B. (Most Cells) [2] 
PKB – Protein Kinase B: A protein which when phosphorylated is responsible for many cell 
functions including insulin signaling. (Most Cells) [2] 
PKC - A protein which activates MAPK pro-inflammatory pathway. (Most Cells) [14] 
Q – Perfusion Flow Rate: Perfusion of glucose from the intestines to the visceral adipose tissue. 
RAGEs – Receptors for AGEs: Receptors that facilitate absorption of advanced glycated end 
products. (Most Cells) [44] 
SOCS - Suppressors of Cytokine Signaling: Anti-inflammatory proteins transcribed by STATs 
which inactivate JAK proteins in inflammatory process. (Most Cells) [13] 
STAT - Signal Transducer and Activator of Transcription: Transcription factor proteins activated 
by janus kinase proteins to being production of pro-inflammatory cytokines and SOCSs. (Most 
Cells) [13] 
T2DM – Type 2 Diabetes Mellitus: A glucose metabolic disease which affects the cell's ability to 
properly respond to insulin. [1] 
VAT – Visceral Adipose Tissue: Adipose tissue that directly surrounds major organs in the 
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Type 2 Diabetes Mellitus (T2DM) is a metabolic disease that affects glucose homeostasis 
[1]. Approximately 200,000 Americans per year are diagnosed with T2DM and a total of 463 
million people globally are affected by several health complications associated with prolonged 
presence of high glucose levels including: neuropathy, kidney failure, and increased risk of heart 
attacks and strokes [1]. Significant T2DM symptoms include impaired insulin action, 
hyperglycemia, hyperlipidemia, hyperinsulinemia, and chronic inflammation [1]. Although 
researchers have tied this disease to diet and epigenetic factors, the primary cellular pathology 
remains elusive. Currently, researchers have proposed different mechanisms of action that 
directly affect insulin action: lipid accumulation in tissue, lipopolysaccharides, pro-inflammatory 
cytokines that cause chronic inflammation, and hyperinsulinemia. In order to ascertain the 
T2DM mechanism of action, we must understand insulin action within the cells, associated 
organs, glucose metabolism, and chronic inflammation. 
Because prolonged high concentrations of glucose are neurotoxic, insulin exerts different 
effects on skeletal muscle, liver, and adipose tissue in order to control significant increases of 
blood glucose concentrations. The pancreas secretes insulin once it senses glucose concentrations 
significantly above a certain threshold [2]. Once secreted, insulin binds to specific insulin 
receptors in the organs to start an intracellular process involving phosphoinositide 3-kinase 
(PI3K) and protein kinase B (PKB), also known as Akt, to translocate the vesicles containing 





This process involves the activation of insulin receptor substrate (IRS) once the insulin binds to 
the insulin receptor [2]. The IRS then activates PI3K to convert phosphatidylinositol 4,5-
biphsophate (PIP)2 to PIP3 [2]. PIP3 then activates PKB which then facilitates the translocation 
of glucose transporter type 4 (GLUT4) to the cell membrane [2]. 
Not only does insulin initiate GLUT4 translocation to the cell membrane, but it also 
affects different metabolic processes dependent on the organ [4]. Insulin overrides normal 
metabolic processes by inhibiting lipid metabolism in skeletal muscle, adipose tissue, and the 
liver to return glucose levels to their baseline levels [2].  Most importantly, insulin inhibits 
glycogenolysis the cleavage of glycogen --a polysaccharide of glucose -- stored in the liver and 
skeletal muscle functions to decrease glucose levels, to focus on glycolysis from absorbed 
glucose [4]. Insulin also stimulates the liver and skeletal muscle to begin glycogenesis in an 
effort to store glucose as glycogen stores inside those organs [4].  When insulin is high, it also 
slows lipolysis of triglycerides into free fatty acids and therefore reduces their release into the 
Figure 1 [3]: Basic Insulin Action 




plasma by adipose tissue. The adipose tissue also converts absorbed glucose into glycerol [4].  
After the lowering of glucose in the plasma by these responses to insulin, the pancreas begins to 
release glucagon to help maintain g exerts these effects in tandem with the glucagon hormone to 
assist in maintaining glucose homeostasis after there is no longer glucose intake into the body 
[5].  The pancreas secretes glucagon in response to the blood glucose levels dipping below the 
baseline levels [5]. Glucagon binds to glucagon receptors in the liver and skeletal muscle to 
begin glycogenolysis [5]. Glycogen phosphorylase cleaves a glucose-1-phosphate from the 
terminus of glycogen molecules until all the glucose stored in glycogen [5]. After the liver and 
skeletal muscle deplete their glycogen stores, glucagon promotes gluconeogenesis which 
generates glucose from non-carbohydrate sources including lipids, glycerol, and proteins to 
maintain basal blood glucose levels [5]. These processes can be seen in Figure 2.  
Figure 2 [6]: Glucagon Effect on Hepatic Cell. In gluconeogenesis, PKA begins the transcription of G6PC and 
PCK1 in the nucleus, which then promote the conversion of non-glycogen sources such as amino and fatty acids into 
glucose [6]. The plus marks indicate an upregulation of processes [6]. The large arrow indicates the transport of 
glucose through the GLUT1 membrane protein. 
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Insulin resistance results in a decrease of GLUT4 to the cell membranes and thereby affects the 
ability of the liver, adipose tissue, and skeletal muscles take glucose out of the plasma to 
maintain glucose homeostasis [5]. Without proper insulin action in the body, important organs 
involved in glucose homeostasis not only fail to absorb glucose with GLUT4, but also fail to 
switch metabolism targets: 1) failed inhibition of glucagon secretion causes the liver to continue 
to secrete glucose into the bloodstream, 2) the skeletal muscle continues to preferentially 
metabolize fats instead of glucose, and 3) adipose tissue continues to secrete fat into the 
bloodstream [7]. As a consequence, T2DM patients have an inability to preferentially metabolize 
glucose and begin to experience not only higher normal glucose levels, but also prolonged 
exposure to those heightened glucose levels [1]. To find potential mechanisms of actions that 
result in T2DM, researchers have explored the comorbidity of T2DM and obesity, and they 
discovered potential links between fat accumulation and insulin resistance in T2DM patients [8]. 
FATTY ACID ACCUMULATION 
Along with impaired insulin action, T2DM patients experience hyperlipidemia and 
increased lipid content in certain organs [8]. As mentioned earlier, insulin resistance causes the 
adipose tissue to continue to secrete free fatty acids (FFAs) into the bloodstream, in spite of 
insulin binding to its receptors [9]. Concurrently, the insulin resistant liver and skeletal muscle 
continue to absorb FFAs from the bloodstream, and they tend to accumulate FFAs due to an 
impaired metabolism of FFAs [10]. The impaired metabolism of FFAs may be due to 
mitochondrial defects within affected cells since researchers observed a lack of FFA oxidation in 
insulin resistant skeletal muscle [10]. The liver and skeletal muscle absorb FFAs with the 
translocation of the CD36 membrane protein [11]. CD36 translocation to the cell membrane 
requires an influx of Ca2+ ions which are controlled by ion transporters [11]. Therefore an 
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abnormal influx of Ca2+ ions into cells can cause upregulated translocation of CD36 to the cell 
membrane, leading to FFA accumulation within upregulated CD36 protein-specific tissue. 
Accumulation of FFAs can increase the concentration of harmful intracellular FFA metabolites, 
such as ceramide and palmitic acid, which can cause deleterious effects including impaired 
insulin action through inhibition of Akt processes [10]. Researchers have experimented with 
insulin sensitivity in CD36 knock-out (CD36KO) mice [12]. When compared to their diabetic 
controls, CD36KO mice experienced increased insulin sensitivity [12]. However, researchers 
were not able to completely cure diabetic rats by inhibiting CD36 production. This suggests that 
there may be additional cellular processes affecting cellular insulin action. To this end, 
researchers have also observed FFA metabolites activating cellular pro-inflammatory processes 
through binding to inflammatory receptors, potentially overstimulating pro-inflammatory 
processes that lead to the accumulation of intracellular pro-inflammatory cytokines [10]. 
INFLAMMATION 
The inflammation cellular process involves the presence of pro-inflammatory and anti-
inflammatory cytokines [13]. The balance of each interaction results in an acute activation of an 
inflammatory state of cells that should resolve over time [13]. An imbalance in these interactions 
may lead to a prolonged inflammatory environment which can cause a variety of chronic 
illnesses and diseases such as rheumatoid arthritis and lupus nephritis [13]. While the 
inflammation process can span in various tissues and organ systems, we will focus on the 
inflammation that occurs on a single cell [13].  
Activated macrophages are the primary producers of inflammatory cytokines which up-
regulate the inflammatory process [13]. Up-regulation results in an increase in cytokine 
expression within cells and a cascade of pro-inflammatory effects through three primary 
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pathways: nf-kB pathway, MAPK pathway, and the JAK/STAT pathway [13]. The nf-kB 
pathway controls the pro-inflammatory cytokine expression as well as cell recruitment that 
contribute to the pro-inflammatory response [13]. The MAPK pathway includes a family of 
serine/threonine protein kinases that activate the cellular responses of inflammatory cytokines 
and other proteins [13]. Through the activation of the MAPK process, p38 transcription factors 
phosphorylate to initiate transcription factors in the cell nucleus, thus activating the 
inflammatory response [13]. The JAK/STAT pathway is unique to the previous processes as 
extracellular factors such as interleukin-6 (IL-6) directly affect gene expression [13]. JAKs 
associated with their respective receptors phosphorylate each other to activate their respective 
STATs via phosphorylation [13]. STATs then dimerize before translocating to the nucleus, 
where they bind to gene promoter regions to upregulate transcription of inflammatory genes [13]. 
The inflammatory cytokines expressed in the nucleus exit the cell and bind to other cell surface 
receptors [13]. From these inflammatory pathways, researchers have observed how inflammation 
can directly cause insulin resistance through intracellular insulin signaling mechanisms [14]. 
Researchers have been able to map certain inflammatory pathway products that have an 
effect on insulin resistance. Such products have been shown to inhibit the IRS protein directly 
[14]. Upstream products include the PKC, JNK, and IKK proteins which are activated by several 
substrate receptors including the LTB4, ANG II, FFAs, TNF-α, and IL-1β [14]. Researchers 
believe these proteins may cause insulin resistance by presently unknown processes [14]. In 
addition to the PKC, JNK, and IKK proteins, downstream inflammatory substrates such as the C-
Jun and nf-κB induce production of inflammatory molecules and inflammasomes [14]. 
Inflammasomes and inflammatory molecules induce further activation of inflammatory receptors 
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once secreted outside the cell [14]. Furthermore, inflammatory molecules can also directly 
inhibit IRS function [14]. These pathways are shown in Figure 3. 
  
Figure 3 [14]: Inflammatory Effect on Cellular Insulin Action. Cellular pathways for inflammation to affect 
insulin response in a skeletal muscle cell.  
The activation of the JAK/STAT pathway also results in the expression of anti-
inflammatory cytokines suppressor of cytokine signaling (SOCSs) which bind to JAK to 
suppress its activation [13]. Researchers have proposed that the JAK/STAT pathway, through the 
suppression of SOCSs, contribute to let pro-inflammatory processes run rampant [13]. 
Researchers have experimented with SOCS KO mice, discovering that such mice experienced 
increased insulin resistance when compared to control mice, suggesting that a rampant 
inflammatory process through the JAK/STAT pathway may have a significant contribution to 
insulin resistance [15]. Furthermore, researchers have observed that JAK/STAT KO diabetic 
mice demonstrate increased insulin sensitivity compared to control diabetic mice [16]. What is 
most interesting is that one study measured insulin sensitivity between JAK/STAT KO mice in 
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different organs [17]. They observed that liver-specific JAK/STAT and adipose-specific 
JAK/STAT KO mice had improved insulin sensitivity compared to diabetic mice. However, 
mice with both liver- and adipose-specific JAK/STAT KO retained insulin sensitivity 
comparable to healthy control mice despite liver steatosis, which is normally associated with 
insulin insensitivity [17]. These results suggest that the interaction between the liver and adipose 
tissue has a significant role in the development of insulin resistance. In addition, it is possible to 
assume that the JAK/STAT pathway has a significant contribution to the development of insulin 
resistance in the pathology of T2DM. When we consider both the symptomatology of chronic 
inflammation and fat accumulation within tissue, we find that beta amyloids can cause all these 
symptoms in T2DM patients.  
APPs AND BETA AMYLOIDS 
Beta amyloids, or amyloid betas, are processed peptides products of length 39-43 amino 
acids [18]. Extracellular accumulation of beta amyloids have been implicated in Alzheimer’s 
disease and more recently T2DM [18]. Beta amyloids can exert insulin insensitivity through 
direct and indirect processes. The membrane-binding of beta amyloids can cause depolarization 
of cell membranes, which may in turn cause an overstimulation of CD36 translocation to the cell 
membrane [19]. This increases the FFA influx and can result in accumulation of FFA and 
harmful FFA metabolites, thereby decreasing insulin activity [10]. Furthermore, beta amyloids 
overstimulate the JAK/STAT pathway, causing chronic inflammation in the cells [20]. Through 
the JAK/STAT pathway, beta amyloids lead to an increase in the expression of pro-inflammatory 
cytokines [20]. In normal cellular inflammatory processes, the nucleus would begin to produce 
SOCS proteins that directly inhibit JAK activity [21]. However, beta amyloids can stimulate the 
epidermal growth factor receptor (EGFR) which can inactivate the SOCSs, hindering the cell’s 
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ability to shut down its own anti-inflammatory pathway [21]. Another potential outcome of the 
inactivation of SOCS can lead to intracellular SOCS accumulation [22]. The cell may continue to 
upregulate SOCSs in a futile attempt to suppress the JAK/STAT inflammatory pathway, leading 
to an accumulation of intracellular SOCSs [22]. These SOCSs can negatively affect insulin 
action by the deactivating IRS proteins through inhibition of tyrosine phosphorylation [22]. In 
addition, SOCSs can also increase production of ceramide which inhibits PI3K and Akt proteins 
[23][24]. Not only are PI3K and Akt integral to the final activation of GLUT4 translocation, 
these proteins also mediate several other processes, such as cell migration and recruitment [25], 
which researchers have observed to be hindered in T2DM and other chronic inflammatory-
disease patients [26].  
As people age, they begin to experience the effects of beta amyloid accumulation in 
tissue and blood [27]. However, significant accumulation of beta amyloids appears to not happen 
in all aging people sufficiently to cause neurodegenerative diseases. This suggests that there are 
other parameters that cause either the upregulated expression of beta amyloids or the decrease of 
beta amyloid clearance or both [28]. Chen has suggested that particulate air pollution may be 
involved in the upregulation of misfolded beta amyloids that cause both Alzheimer’s and 
Parkinson’s diseases [28]. 
Beta amyloids are byproducts of amyloid precursor proteins (APPs) processing. APPs are a class 
of transmembrane proteins that undergo post-translational modification that result in proteolytic 
cleavage to peptide fragments and other products [29]. Through secretase (beta and gamma) 
cleavage of APPs, beta amyloids are generated at varying lengths [29]. Although researchers 
have investigated the inhibition of gamma secretase as a means of preventing beta amyloid 
production, there appears to be several underlying processes that also produce beta amyloids 
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from APPs, which render the inhibition of gamma secretase paradoxically ineffective [29]. 
Researchers investigating Alzheimer's Disease (AD) have narrowed down beta amyloids 1-40 
and 1-42, marked by the length of their peptide chain, as the most harmful beta amyloids [30]. 
These beta amyloid species have been linked to T2DM with a potential shared pathology with 
AD [31]. Typically proteolytic degradation of beta amyloids account for the majority of its 
clearance [32]. While there are many classes of proteins which can degrade beta amyloids, we 
chose to focus on neprilysin (NEP) due to the abundance of literature that characterizes it. 
NEP is a zinc-metalloprotease which faces the plasma side of the cell. It primarily degrades 
peptides of 40 to 50 residue lengths, and NEP has the ability to degrade more toxic beta amyloid 
oligomers as well as monomers [33]. Researchers have discovered that NEP KO mice 
experienced increased levels of beta amyloids in the brain [33]. Furthermore, researchers have 
transferred the NEP gene into AD transgenic mice and discovered a reversal of amyloid-like 
pathology and improvements in animal behaviors [33]. Baseline NEP tissue concentrations in 
people appears to decrease with age, and researchers suggest that this reduction may lead to 
increased risk of beta amyloid aggregation in cerebral amyloid angiopathy of AD patients [33]. 
Other notable protein degradation mechanisms include other classes of zinc-metalloproteases 
other than NEP, NEP-like proteases, endothelin-converting enzymes, angiotensin-converting 
enzyme, matrix-metalloproteases, insulin-degrading enzymes, serine proteases, and many more 
[34]. However, it is unknown the extent to which decreased levels of degradation proteins 
contribute to the pathogenesis of beta amyloid accumulation. An abnormal clearance of beta 
amyloids due to protein modification by glycation, non-enzymatic glucose addition, may also 
contribute more to beta amyloid accumulation. Paired with hyperglycemia and impaired glucose 
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clearance, glycation may occur more often in individuals at-risk for developing diabetes, 
compared to healthy controls. 
GLYCATION OF BETA AMYLOIDS 
Glycation typically involves a protein or a lipid, covalently binding to a glucose, fructose, 
or glucose/fructose derivatives in a multistep reaction process [35]. 
 Figure 4[36]: Glycation Reaction Mechanism to Form Advanced Glycated End Products. 
Glycation begins with a sugar molecule non-enzymatically binding to a free amino acid, 
typically a lysine or arginine residue, to form a Schiff base [37]. This Schiff base undergoes 
reversible rearrangement (Amadori Rearrangement) to form a more stable Amadori product [37]. 
An Amadori product can undergo further stabilization through a formation of an adduct or 
protein crosslink which becomes practically irreversible [37]. Further environmental interactions, 
typically oxidation, converts the Amadori product to form a variety of advanced glycation end 
products (AGEs) [37]. Researchers have found that AGEs are responsible for a variety of chronic 
conditions including inflammation [37]. AGEs tend to accumulate over time since its 
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modifications decrease clearance rates in the body [37]. The rate at which beta amyloids are 
glycated is dependent on the type of sugar binding to them [37]. Researchers have observed that 
fructose has a glycation rate tenfold to that of glucose [38]. While epigenetic predisposition to 
T2DM is important towards the pathogenesis of T2DM, the prolonged presence of glucose due 
to high-glucose diets may potentially cause increased glycation within patients [1][39].  
Researchers have found that in high glucose environments, beta amyloids experience a 
decrease in clearance similar to that of beta amyloids in patients with London and Sweden 
genetic disorders which result in the N-linked glycosylation of beta amyloids [39]. More 
specifically, the species of beta amyloids in question are 1-40 and 1-42. Although researchers 
have linked beta amyloids 1-42 to most physiological problems associated with Alzheimer’s, this 
protein has a tendency to aggregate into fibrils which accumulate mostly in the brain [40]. 
However, glycation of beta amyloids 1-42 has been proven to decrease the concentration of beta 
amyloid 1-42 fibrils, which suggests that glycated beta amyloid 1-42 exists as a peptide rather 
than a fibril [41]. This corroborates with other studies investigating beta amyloid 1-40 and 1-42 
plasma concentrations between healthy and T2DM patients. Researchers observed a total 
decrease of plasma beta amyloids in T2DM patients compared to controls, but an increase in the 
ratio of plasma 1-42 to 1-40 beta amyloids compared to controls [42]. Although the plasma 
concentration of beta amyloids decreases in T2DM patients, their tissue beta amyloid 
concentration is significantly greater than those of a control patient [43]. This suggests that 
tissues are absorbing beta amyloids at a greater rate likely due to the prolonged presence of beta 
amyloids potentially due to glycation in T2DM patients. Receptors of AGEs (RAGEs) bind to 
glycated beta amyloids from the bloodstream and deposit bound proteins into organ tissue [44]. 
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RAGEs appear to bind to beta amyloid peptides more than their oligomer counterparts as well as 
recruit more RAGEs to the apical blood vessel membrane [44].  
Therefore, it may be important to study the accumulation of beta amyloids, glycated and 
non-glycated species, to ascertain if its significant accumulation can be the primary cause of 
insulin resistance in T2DM patients. So far, we observed that FFAs can exert insulin resistance 
by affecting both upstream and downstream insulin processes. In addition, we observed that the 
JAK/STAT pathway can not only exacerbate FFA-related insulin resistance but also inhibit 
upstream insulin processes. A potential unifying mediator of these symptoms may be related to 
beta amyloids. Beta amyloids can exert chronic inflammation as well as lipid accumulation in 
cells. We attempted to study the potential effects of diet on the accumulation of beta amyloids, 
glycated and non-glycated species, by creating a multi-compartment model using MATLAB. 
 
MULTI-COMPARTMENT MODELING 
Using a system of ordinary differential equations researchers can create multi-
compartment models to predict pharmacokinetic concentration profiles of several substances. 
Along with the basic assumptions used for multi-compartment modeling, we used additional 
assumptions to simplify the complex systems of glucose homeostasis and beta amyloid 
production. The differential equations for this model are listed in Appendix 1. The parameters for 
the rate constants are given in Appendix 2. 
MODELING OF GLUCOSE HOMEOSTASIS 
Our purpose in creating this multi-compartment model is to observe how diet can affect 
the accumulation of beta amyloid species in specific organs. We simulated glucose homeostasis 
14 
 
in our multi-compartment model to be able to simulate long term effects of a high/low glucose 
diet and compare the differences between each respective beta amyloid species accumulation.  
Our glucose homeostasis model only includes the primary organs involved in glucose 
absorption and insulin action as compartments: the blood in the central compartment (i.e. the 
circulatory system), intestines, visceral adipose tissue (VAT), pancreas, liver, and skeletal 
muscle of a 70 kg male. The volume of the compartments represent the blood volumes inside 
each compartment, and the blood flow rates represent the average blood flow rates from the heart 
to each specific organ. We set the baseline blood glucose concentration at ~85 mg/dL. We 
assumed that the brain consumes glucose from the circulatory system at a constant rate. 
Furthermore, we added a glucose dose representing a meal that has a flow-rate from the food to 
the intestines. The glucose dose is representative of the typical glucose mass in a dinnertime 
meal. Studying peritoneal absorption of nutrients as a method of dialysis, researchers have 
observed a potential for the perfusion of nutrients from the intestines to the surrounding cells 
[45]. We represented this perfusion as a flow from the intestinal compartment to the VAT 
compartment. The table containing the values of the volumes and blood flows between each 
compartment used are listed in Appendix 2. The blood flows between each compartment are 
shown in Figure 5. 
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Figure 5: Multi-Compartment Model. The blood flows begin from the circulatory system and flow to each organ 
listed above. The visceral adipose tissue, intestines, and pancreas compartment have an exit flow directly to the liver 
representing the portal vein. The portal vein directly flows into the circulatory system. 
We first modeled the glucose, glucagon, and insulin concentration profiles after a single 
meal. Glucagon and insulin follow the same compartmental model as that of glucose. The 
pancreas appropriately secretes each of these hormones by detecting differences in glucose 
concentration within its compartment [2]. At homeostasis, the pancreas secretes an appropriate 
amount of glucagon and insulin to maintain their baseline hormone concentration in the model. 
At fasting, the pancreas will secrete its baseline glucagon rate to prevent hypoglycemia in the 
model, and insulin will inhibit the secretion of glucagon when the blood glucose concentration 
rises above 110 mg/dL. We use data from a glucose meal study between pre- and post-gastric 
bypass patients to match the parameters observed in patients with a high glucose meal [46]. 
 
 
Figure 6: Glucose Concentration Profile after Ingesting 50 g glucose meal.    
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Insulin and glucagon are assumed to be eliminated by binding to their respective 
receptors via 1st order elimination. Therefore we assumed that the insulin receptor only existed 
in the VAT, liver, and skeletal muscle compartments and that insulin is eliminated in those 
organs. Insulin activates additional glucose absorption terms in the VAT, liver, and skeletal 
muscle dependent on the changes of insulin concentrations within respective compartments 
baseline insulin concentrations. Glucagon is eliminated in the liver compartment and increases 
the glucose secretion term from the liver via glycogenolysis. We assume that there is an infinite 
storage of glycogen within the liver through successive meals.  
We modeled the variable secretion and inhibition of insulin and glucagon as well as their 
effects on specific organs with effect modeling and fractional bound terms from the respective 
hormone concentration baselines. The dissociation constant was adjusted within the fractional 





  Figure 7: Insulin and Glucagon Fractional Change Profile after 50 g glucose meal.  
We then ran the model for over extended periods of 3 regular meals over 24 hours. We 
added dosages of the same 50 g glucose meal at 0 hour, 4 hour, and 8 hour to represent meals at 
8 AM, 12 PM, and 8 PM. The purpose of this was to simulate glucose concentration profiles 
after a patient consumes only high glucose meals throughout the course of a day. We later ran 
this model to simulate high-glucose meal consumption over the course of 30 years in order to 
observe how a high-glucose diet can affect the accumulation of beta amyloid species over an 
extended period of time. 
 
Figure 8: Glucose Concentration Profile after three 50 g glucose meals over the course of a day. 
Doses were given at 0, 4, and 12 hours. At 0 hours we administer the first meal. 
We also modeled a low GI meal, represented as a 5 g glucose meal, so that the glucose 
concentration would not activate insulin secretion in the model. The glucagon secretion rate 
would remain constant due to the lack of increased insulin inhibition. These profiles are listed in 




Figure 9: Glucose Concentration Profile in Circulatory System after a 5 g glucose meal. The glucose 
meal is administered at 0 hour. 
 
Figure 10: Insulin and Glucagon Fractional Concentration Profiles in Circulatory System after a 5 g 
glucose meal. Since the pancreas blood glucose concentration did not rise above 110 mg/dL, there is no 





Figure 11: Glucose Concentration Profile in Circulatory System after three 5 g Glucose Meals. Doses 
were given at 0, 4, and 12 hours. We administered the first meal at 0 hours. 
We ran the glucose profiles from the glucose homeostasis model linearly with the beta 
amyloid and glycation model to determine the effects of glucose concentrations on the glycation 
of beta amyloids in their respective compartments. To maintain the relative simplicity of our 
model, we did not simulate the gradual increase in the baseline glucose concentration observed 
in patients who begin to develop T2DM [1]. 
BETA AMYLOID & GLYCATION REACTION 
We included both glycated and non-glycated beta amyloids in our model in order to 
observe the effects of a high/low GI meal on their accumulation within specific compartments. 
We wanted to investigate if we could observe significant accumulation of beta amyloids species 
in the liver, VAT, and skeletal muscle, and whether the potential of insulin resistance occurred 
simultaneously or successively in those compartments. 
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Non-glycated beta amyloids and glycated beta amyloids share the same basic 
compartment model for glucose homeostasis. We assumed that the primary generation of beta 
amyloids were from the post-translational modifications of APPs. Therefore, we accounted for 
beta-amyloid generation as a constant in the model. The tissues with the highest APP expression 
were the intestines, pancreas, and the brain [47]. We included the APP expression in the brain 
into our model by adding a generation term into the circulatory system. We assumed that NEP 
were the most significant source of beta amyloid elimination from the model. Tissues with the 
highest NEP expression were the intestines, liver, and circulatory system from the brain [48]. 
Assuming that there is constant NEP expression within tissues, we used the same effect model 
with fractional bound terms to model beta amyloid elimination. We adjusted the elimination rate 
constant to match the half-life of beta amyloids in plasma. Although we originally set the 
generation of beta amyloids to maintain a baseline concentration, research has shown that beta 
amyloids naturally accumulate in the blood potentially due to decreased expression of tissue-
bound NEP in the brain. Therefore we adjusted the elimination of beta amyloids to decrease 
linearly with time to represent that decrease [49]. 
Lastly, we modeled the glycation reaction as a 2nd order reaction dependent on the 
glucose and beta amyloid concentration within the compartment. We assumed the fractional 
change of the accumulation of beta amyloids to be based on measurements from blood beta 
amyloid concentrations throughout the lifespan We adjusted the baseline fractional accumulation 
of beta amyloids to be similar to that of the measured beta amyloid changes over the course of 30 
years [50]. Since we assumed no reversible reaction occurs in the model, the glycation rate 






We applied a sensitivity analysis to the reaction rate constant to determine how glycated 
beta amyloid concentrations are affected by a high and low GI meal. We also applied the same 
analysis to the perfusion rate of glucose from the intestines to the VAT to observe how the 
increased perfusion of VAT would affect the accumulation of glycated amyloid beta 
concentrations.  
We completed the sensitivity analyses on the effect of the glycation reaction rate (krxn) 
and perfusion flow rate (Q) by multiplying the rate values by factors of 0.01, 0.02, 0.05, 0.1, 0.2, 
0.5, 1, 2, 5, and 10. We simulated consumption of high-glucose meals over the course of 30 
years to observe the fractional changes of non-glycated beta amyloids and glycated beta 
amyloids within the model. To decrease computing time, we stored only the beta amyloid and 
glycated beta amyloid fractional changes at the end of each day. 
VARIABLE REACTION RATE 
We repeated the high GI meals over the course of 30 years to observe any significant fractional 
changes between the variable glycation rates. The results can be seen below in Figure 12-15. 
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Figure 12: Fractional Change of Beta Amyloid Concentrations in Blood Circulatory System with 50 g 
Glucose Meal. The fractional change represents the change increase from the baseline beta amyloid concentration at 
time 0. 
Figure 13: Effect of Glycation Rate on Final Fractional Change of Beta Amyloid with 50 g Glucose Meal. We 






















































Figure 14: Fractional Change of Glycated Beta Amyloids in Blood Circulatory System with 50 g Glucose 
Meal. The fractional change represents the fractional increase of beta amyloid concentrations compared to baseline 
beta amyloid concentrations at time 0. 
Figure 15: Effect of Glycation Rate on Final Fractional Change of Glycated Beta Amyloid with 50 g Glucose 
Meal. We varied the glycation rate using a sensitivity analysis at the end of 30 years. The fractional change 
represents the fractional increase from baseline concentrations. 
The reaction rate that achieved the highest fractional change of glycated beta amyloids 
and non-glycated beta amyloids was 0.1*krxn resulting in a 1.71 and 1.30 fractional increase 























































increased. The same behavior was observed for the non-glycated beta amyloid final fractional 
changes. 
We also compared the accumulation of glycated beta amyloids within the VAT, liver, and 
skeletal muscle across the variable glycation rate seen in Figure 16. 
Figure 16: Glycation Rate Effect on Final Fractional Change of Glycated Beta Amyloid with 50 g Glucose 
Meal in Compartments. We varied the glycation rate using a sensitivity analysis after 30 years. The fractional 
change represents the fractional increase from baseline concentrations. 
We observed that the VAT, liver, and skeletal muscle compartments appear to experience 
the same final concentration trends in relation to the circulatory system final glycated beta 
amyloid concentrations). Between the compartments, the liver had the highest glycated beta 
amyloid fractional changes, then the skeletal muscle, then the VAT. The differences between the 
organ compartments also appeared to diminish as the glycation rate increased. 
We repeated the glycation rate sensitivity analysis with a 5 g glucose meal over the 






























Figure 17: Glycation Rate Effect on Final Fractional Change of Beta Amyloid with 5 g Glucose Meal. We 
varied the glycation rate using a sensitivity analysis. The fractional change represents the fractional increase from 
baseline concentrations. 
 
Figure 18: Glycation Rate Effect on Final Fractional Change of Glycated Beta Amyloid with 5 g Glucose 
Meal. We varied the glycation rate using a sensitivity analysis. The fractional change represents the fractional 
increase from baseline concentrations. 
As shown in Figures 17-18, we observed the same optimal glycation rate behavior for the 
low GI meal data as we did with the high GI meal data. However, for low GI meals we observed 
the highest glycated beta amyloid fractional change and non-glycated beta amyloid fraction 




















































meals resulted in the same highest non-glycated beta amyloid fractional change of 1.30 in the 
circulatory system compartment. We also observed the differences of glycated beta amyloid 
fractional changes in low GI meals. The results can be seen in Figure 19. 
 
Figure 19: Glycation Rate Effect on Fractional Change of Glycated Beta Amyloid with 5 g Glucose Meal in 
Compartments. We varied the glycation rate using a sensitivity analysis. The fractional change represents the 
fractional increase from baseline concentrations. 
From Figure 19 we observed the same behaviors of the final fractional changes of the 
glycated and non-glycated beta amyloids. Looking at the incremental differences between the 
compartments, the liver had the highest fractional change, then the skeletal muscle, then the 
VAT. These results suggest that the accumulation of beta amyloid species in the blood 
compartments of the organs may rise uniformly, and that insulin resistance may occur 
simultaneously within organs. 
VARIABLE PERFUSION RATE 
We analyzed the effect of perfusion from the VAT compartment to the intestines 






























Figure 20: Max and Min Glucose Concentrations in VAT Compartment. (A) exhibits the different 
maximum concentrations in VAT after a high glucose meal by varying perfusion rate. (B) exhibits the 
different minimum concentrations in VAT after a high glucose meal with same variation. 
The perfusion of glucose flow into the VAT from the intestines compartment resulted in 
minimal variance between maximum and minimum glucose concentrations in the VAT 
compartment after a high glucose meal. The VAT compartment reached its maximum glucose 
concentration at the baseline perfusion flow rate.  Increasing and decreasing the perfusion rate 
both decreased the maximum VAT glucose concentration. We also observed similar behavior in 
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We varied the perfusion flow rate from the intestine compartment to the VAT 
compartment in a sensitivity analysis described earlier. While repeating high GI meals over the 
course of 30 years, we observed an optimal maximal accumulation of glycated and non-glycated 
beta amyloids in the circulatory system compartment. The results can be seen in Figure 21-22. 
Figure 21: Perfusion Rate Effect on Final Fractional Change of Beta Amyloid with 50 g Glucose Meal. We 
varied the perfusion rate using a sensitivity analysis from the glucose in the intestines to the VAT. The fractional 
change represents the fractional increase from baseline concentrations. 
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Meal. We varied the perfusion rate using a sensitivity analysis from the glucose in the intestines to the VAT. The 
fractional change represents the fractional increase from baseline concentrations. 
Keeping the glycation rate constant to 1*krxn, we observed that the highest fractional 
change of glycated beta amyloids at 0.5*Q and 1.673. However, we observed an inverse 
relationship between the maximal and minimal final fractional change values of the glycated and 
non-glycated beta amyloids. The minimal fractional change of non-glycated beta amyloids 
corresponded to the maximal fractional change of glycated beta amyloids across the sensitivity 
analysis. Additionally, the differences between the final fractional changes varied significantly 
less than the variable glycation rate values, with changes varying in the tenths rather than the ten-
thousandths. 
 
Figure 23: Perfusion Rate Effect on Final Fractional Change of Beta Amyloid with 5 g Glucose Meal. We 
varied the perfusion rate using a sensitivity analysis from the glucose in the intestines to the VAT. The fractional 



























Figure 24: Perfusion Rate Effect on Final Fractional Change of Glycated Beta Amyloid with 5 g Glucose Meal 
in Organs. We varied the perfusion rate using a sensitivity analysis from the glucose in the intestines to the VAT. 
The fractional change represents the fractional increase from baseline concentrations. 
We ran the variable perfusion analysis with a low GI meal as seen in Figure 23-24. We 
observed that the glycated beta amyloid final fractional changes varied insignificantly between 
the sensitivity factors. The perfusion rate appeared to have little effect on the final non-glycated 
beta amyloid fractional as well, but the final fractional change did increase in response to 
increasing perfusion rate. 
In Figure 25, we also observed insignificant glycated beta amyloid fractional change 
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Figure 25: Perfusion Rate Effect on Final Fractional Change of Glycated Beta Amyloid with 5 g Glucose Meal 
in Compartments. We varied the perfusion rate using a sensitivity analysis from the glucose in the intestines to the 
VAT. The fractional change represents the fractional increase from baseline concentrations. 
With a low GI meal, the VAT glycated beta amyloid concentrations appeared to increase 
as the perfusion rate increased from 0.1*Q. The other glycated beta amyloid concentrations did 
not appear to change as much as that in the VAT compartment. We observed some changes in 
those compartments across the perfusion flow rates, but considering the scale smaller than ten-






























The purpose of this model was to determine how the effects of high and low GI meals 
affected the final fractional change of beta amyloid species in blood compartments. Between the 
high and low GI meals, we applied a sensitivity analysis to the glucose perfusion from the 
intestines to the VAT blood compartments and to the glycation rate. We specifically wanted to 
observe the accumulation of beta amyloid species in the VAT, liver, and skeletal muscles due to 
their important role towards the pathogenesis of insulin resistance in T2DM. 
EFFECT OF HIGH AND LOW GI MEALS 
From the results in Figure 12, we observed that there was an optimal glycation rate that 
yielded the greatest concentration of glycated beta amyloids in the model. The degree to which 
the glycation rate affected the accumulation of glycated beta amyloids depended on the amount 
of glucose in the meal. We observed greater variability as the glycation rate increased, but as the 
glycation rate decreased below 0.1*krxn, the final fractional change of the glycated beta 
amyloids did not appear to vary as greatly. Furthermore, we observed even less variability in the 
final fractional changes of beta amyloid species with a low GI meal. The circulatory system's 
non-glycated and glycated beta amyloid fractional changes appeared to mirror fractional changes 
to those of the VAT, liver, and skeletal muscle compartments. We concluded that the glycation 
rate had an overall effect on the entire system’s rate of accumulation rather than specifically 
within certain compartments. 
The type of GI meal did affect the maximal glycated beta amyloid fractional changes. We 
observed a 0.02 difference between the maximal glycated beta amyloid fractional changes at a 
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high glucose meal and a low one. Although high glucose meals are associated with higher AGEs 
in the body, it is unclear how much of a difference a 0.02 fractional change makes.  
The changes to the perfusion rate between the intestines and VAT compartments had less 
of an impact on the final glycated beta amyloid fractional change than that of the changes to the 
glycation rate. The final fractional changes boiled down to a difference of a magnitude of 
millionths versus thousandths respectively. Although we did observe greater perfusion of glucose 
within the VAT compartment with an increase of perfusion rate, it appeared to have little effect 
on the final glycated fractional changes between the compartments. Therefore perfusion between 
the blood compartments does not appear to contribute significantly to the accumulation of beta 
amyloid species within organs, and thus contribute significantly towards the pathogenesis of 
insulin resistance. 
The accumulation of beta amyloids in these compartments may elucidate the cellular 
development of T2DM over time due to a high glycemic index diet. As mentioned before, beta 
amyloids can not only exert insulin insensitivity but also inflammation and steatosis into organ 
tissue, some of many physiological symptoms in T2DM patients. We propose the potential 
cellular effects beta amyloids may exert on cells in Figure 26. 
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Figure 26: Effects of beta amyloid onto cellular mechanisms. Beta amyloids can directly bind to receptors or 
bind to cell surface membranes to elicit effects on cellular processes that affect inflammation and FFA absorption. 
Figure 26 shows that beta amyloids can exert multiple effects such as inflammation and 
potentially FFA accumulation by binding to specific receptors on cell membranes. Beta amyloids 
can activate the JAK/STAT pathway to induce insulin resistance via inflammation through both 
SOCS inactivation and accumulation. They can also induce cellular FFA absorption which can 
induce the accumulation of harmful metabolites such as ceramides that affect Akt processes, 
which include insulin signaling. There is currently no research on whether inflammation or FFA 
accumulation contributes more to insulin resistance in the tissue, nor whether one symptom 
begets the other. Nonetheless, it is important to note that beta amyloids can induce both of these 
effects. 
Based on the results, we observed little variance in the final fractional changes of beta 
amyloid species between the VAT, liver, and skeletal muscle blood compartments. Although 
glycation rate caused the most variance of final beta amyloid fractional changes, the model did 




To improve the physiological accuracy of the model, future models should include extra 
compartments that represent the organs’ interstitial fluid volumes. Regarding the uptake of 
glycated beta amyloids into tissue, researchers have discovered that AGEs upregulate RAGEs to 
absorb more AGEs into tissue [50]. Depending on how sensitive RAGEs are towards AGE 
concentrations in the bloodstream, small changes to the glycated beta amyloid concentrations 
may promote increased overall tissue beta amyloid concentrations. From the blood compartments 
beta amyloids should absorb into the tissue volume compartments in a protein-binding dependent 
manner. Although beta amyloid concentrations in the blood can correlate with the potential 
accumulated beta amyloids in the organ tissue, it is unclear whether the glycation rate is the most 
significant factor towards the critical accumulation of beta amyloids within the tissues.  
Further improvements made to the code should include a distinction between the beta 
amyloids generated from APP and beta amyloid-protein interactions. An increase of beta 
amyloids may cause the generation of more beta amyloids within compartments that do not 
generate APP in the tissue. Also, the generation of beta amyloids should occur in APP 
expressing tissue (circulatory system, intestine, and pancreas) compartments. The glucose 
perfusion from the intestine to the VAT would more accurately be modeled as flow from the 
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APPENDIX I Differential Equations for ODE Compartmental Analysis 
Collapsed Terms 




= −𝑘𝑐𝑖𝑟𝑜 ∗ 𝑦𝑐𝑖𝑟 𝑔 + 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑔 + 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑔 − 𝑘𝑒𝑙𝑖 𝑔 ∗ 𝑦𝑐𝑖𝑟 𝑔 
𝑑𝑦𝑖𝑛𝑡 𝑔
𝑑𝑡
= 𝑘𝑖𝑛𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑔 − (𝑘𝑖𝑛𝑡𝑜 + 𝑘𝑝𝑒𝑟𝑜 + 𝑘𝑒𝑙𝑖 𝑔) ∗ 𝑦𝑖𝑛𝑡 𝑔 + 𝑘𝑑𝑖𝑠 ∗ 𝑦𝑓𝑜𝑜𝑑 
𝑑𝑦𝑣𝑎𝑡 𝑔
𝑑𝑡
= 𝑘𝑣𝑎𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑔 − (𝑘𝑣𝑎𝑡𝑜 + 𝑘𝑒𝑙𝑖 𝑔 − 𝑘𝑖𝑛𝑠 𝑐𝑜𝑛𝑠 𝑔 ∗ 𝑓𝑣𝑎𝑡 𝑖) ∗ 𝑦𝑣𝑎𝑡 𝑔 + 𝑘𝑝𝑒𝑟𝑜 ∗ 𝑦𝑖𝑛𝑡 𝑔 
𝑑𝑦𝑝𝑎𝑛 𝑔
𝑑𝑡
= 𝑘𝑝𝑎𝑛𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑔 − (𝑘𝑝𝑎𝑛𝑜 + 𝑘𝑒𝑙𝑖 𝑔) ∗ 𝑦𝑝𝑎𝑛 𝑔 
𝑑𝑦𝑙𝑖𝑣 𝑔
𝑑𝑡
= 𝑘𝑡𝑜𝑡 𝑙𝑖𝑣𝑖 𝑔 − (𝑘𝑙𝑖𝑣𝑜 + 𝑘𝑒𝑙𝑖 𝑔 + 𝑘𝑖𝑛𝑠 𝑐𝑜𝑛𝑠 𝑔 ∗ 𝑓𝑙𝑖𝑣 𝑖) ∗ 𝑦𝑙𝑖𝑣 𝑔 + 𝑓𝑙𝑖𝑣 𝑙 ∗ 𝑘𝑙𝑖𝑣 𝑔𝑒𝑛 
𝑑𝑦𝑚𝑢𝑠 𝑔
𝑑𝑡
= 𝑘𝑚𝑢𝑠𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑔 − (𝑘𝑚𝑢𝑠𝑜 + 𝑘𝑒𝑙𝑖 𝑔 − 𝑘𝑖𝑛𝑠 𝑐𝑜𝑛𝑠 𝑔 ∗ 𝑓𝑚𝑢𝑠 𝑖) ∗ 𝑦𝑚𝑢𝑠 𝑔  




= −𝑘𝑐𝑖𝑟𝑜 ∗ 𝑦𝑐𝑖𝑟 𝑙 + 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑙 + 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑙 − 𝑘𝑒𝑙𝑖 𝑔 ∗ 𝑦𝑐𝑖𝑟 𝑙 
𝑑𝑦𝑖𝑛𝑡 𝑙
𝑑𝑡
= 𝑘𝑖𝑛𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑙 − (𝑘𝑖𝑛𝑡𝑜 + 𝑘𝑝𝑒𝑟𝑜) ∗ 𝑦𝑖𝑛𝑡 𝑙 
𝑑𝑦𝑣𝑎𝑡 𝑙
𝑑𝑡
= 𝑘𝑣𝑎𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑙 − 𝑘𝑣𝑎𝑡𝑜 ∗ 𝑦𝑣𝑎𝑡 𝑙  + 𝑘𝑝𝑒𝑟𝑜 ∗ 𝑦𝑖𝑛𝑡 𝑙 
𝑑𝑦𝑝𝑎𝑛 𝑙
𝑑𝑡
= 𝑘𝑝𝑎𝑛𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑙 − 𝑘𝑝𝑎𝑛𝑜 ∗ 𝑦𝑝𝑎𝑛 𝑙 + 𝑘𝑔𝑒𝑛 𝑙 ∗ 𝐼𝑝𝑎𝑛 𝑙 
𝑑𝑦𝑙𝑖𝑣 𝑙
𝑑𝑡
= 𝑘𝑡𝑜𝑡 𝑙𝑖𝑣𝑖 𝑙 − (𝑘𝑙𝑖𝑣𝑜 + 𝑘𝑒𝑙𝑖 𝑙) ∗ 𝑦𝑙𝑖𝑣 𝑙 
𝑑𝑦𝑚𝑢𝑠 𝑙
𝑑𝑡







= −𝑘𝑐𝑖𝑟𝑜 ∗ 𝑦𝑐𝑖𝑟 𝑖 + 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑖 + 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑖 − 𝑘𝑒𝑙𝑖 𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑖 
𝑑𝑦𝑖𝑛𝑡 𝑖
𝑑𝑡
= 𝑘𝑖𝑛𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑖 − (𝑘𝑖𝑛𝑡𝑜 + 𝑘𝑝𝑒𝑟𝑜) ∗ 𝑦𝑖𝑛𝑡 𝑖 
𝑑𝑦𝑣𝑎𝑡 𝑖
𝑑𝑡
= 𝑘𝑣𝑎𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑖 − (𝑘𝑣𝑎𝑡𝑜 + 𝑘𝑒𝑙𝑖 𝑖) ∗ 𝑦𝑣𝑎𝑡 𝑖  + 𝑘𝑝𝑒𝑟𝑜 ∗ 𝑦𝑖𝑛𝑡 𝑖 
𝑑𝑦𝑝𝑎𝑛 𝑖
𝑑𝑡
= 𝑘𝑝𝑎𝑛𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑖 − 𝑘𝑝𝑎𝑛𝑜 ∗ 𝑦𝑝𝑎𝑛 𝑖 + 𝑆𝑝𝑎𝑛 𝑖 ∗ 𝑘𝑔𝑒𝑛 𝑖 
𝑑𝑦𝑙𝑖𝑣 𝑖
𝑑𝑡
= 𝑘𝑡𝑜𝑡 𝑙𝑖𝑣𝑖 𝑖 − (𝑘𝑙𝑖𝑣𝑜 + 𝑘𝑒𝑙𝑖 𝑖) ∗ 𝑦𝑙𝑖𝑣 𝑖 
𝑑𝑦𝑚𝑢𝑠 𝑖
𝑑𝑡
= 𝑘𝑚𝑢𝑠𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑖 − (𝑘𝑚𝑢𝑠𝑜 + 𝑘𝑒𝑙𝑖 𝑖) ∗ 𝑦𝑚𝑢𝑠 𝑖  
Non Glycated Beta Amyloids 
𝑑𝑦𝑐𝑖𝑟 𝑏
𝑑𝑡
= −𝑘𝑐𝑖𝑟𝑜 ∗ 𝑦𝑐𝑖𝑟 𝑏 + 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑏 + 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑏 − 𝑘𝑒𝑙𝑖 𝑏 ∗ 𝑓𝑐𝑖𝑟 𝑏 + 𝑘𝑔𝑒𝑛 𝑏
−





= 𝑘𝑖𝑛𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏 − (𝑘𝑖𝑛𝑡𝑜 + 𝑘𝑝𝑒𝑟𝑜) ∗ 𝑦𝑖𝑛𝑡 𝑏 +
𝑘𝑔𝑒𝑛 𝑏
2
− 𝑘𝑒𝑙𝑖 𝑏 ∗ 𝑓𝑖𝑛𝑡 𝑏
−





= 𝑘𝑣𝑎𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏 − 𝑘𝑣𝑎𝑡𝑜 ∗ 𝑦𝑣𝑎𝑡 𝑏  + 𝑘𝑝𝑒𝑟𝑜 ∗ 𝑦𝑖𝑛𝑡 𝑏  −














= 𝑘𝑡𝑜𝑡 𝑙𝑖𝑣𝑖 𝑏 − 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑏 − 𝑘𝑒𝑙𝑖 𝑏 ∗ 𝑓𝑙𝑖𝑣 𝑏  −





= 𝑘𝑚𝑢𝑠𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏 − 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑏  −
𝑘𝑟𝑥𝑛 ∗ 𝑦𝑚𝑢𝑠 𝑔 ∗ 𝑦𝑚𝑢𝑠 𝑏
𝑉𝑚𝑢𝑠
  
Glycated Beta Amyloids 
𝑑𝑦𝑐𝑖𝑟 𝑏𝑔
𝑑𝑡
= −𝑘𝑐𝑖𝑟𝑜 ∗ 𝑦𝑐𝑖𝑟 𝑏 + 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑏𝑔 + 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑏𝑔 − 𝑘𝑒𝑙𝑖 𝑏𝑔 ∗ 𝑓𝑐𝑖𝑟 𝑏𝑔
+







= 𝑘𝑖𝑛𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏𝑔 − (𝑘𝑖𝑛𝑡𝑜 + 𝑘𝑝𝑒𝑟𝑜) ∗ 𝑦𝑖𝑛𝑡 𝑏𝑔 − 𝑘𝑒𝑙𝑖 𝑏𝑔 ∗ 𝑓𝑖𝑛𝑡 𝑏𝑔 +





= 𝑘𝑣𝑎𝑡𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏𝑔 − 𝑘𝑣𝑎𝑡𝑜 ∗ 𝑦𝑣𝑎𝑡 𝑏𝑔  + 𝑘𝑝𝑒𝑟𝑜 ∗ 𝑦𝑖𝑛𝑡 𝑏𝑔 +





= 𝑘𝑝𝑎𝑛𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏𝑔 − 𝑘𝑝𝑎𝑛𝑜 ∗ 𝑦𝑝𝑎𝑛 𝑏𝑔 +





= 𝑘𝑡𝑜𝑡 𝑙𝑖𝑣𝑖 𝑏𝑔 − 𝑘𝑙𝑖𝑣𝑜 ∗ 𝑦𝑙𝑖𝑣 𝑏𝑔 − 𝑘𝑒𝑙𝑖 𝑏𝑔 ∗ 𝑓𝑙𝑖𝑣 𝑏𝑔 +





= 𝑘𝑚𝑢𝑠𝑖 ∗ 𝑦𝑐𝑖𝑟 𝑏𝑔 − 𝑘𝑚𝑢𝑠𝑜 ∗ 𝑦𝑚𝑢𝑠 𝑏𝑔 +
𝑘𝑟𝑥𝑛 ∗ 𝑦𝑚𝑢𝑠 𝑔 ∗ 𝑦𝑚𝑢𝑠 𝑏
𝑉𝑚𝑢𝑠
 
Fractional Bound Terms 
𝑆𝑝𝑎𝑛 𝑖 = 1 + 𝐸max 𝑝𝑎𝑛 𝑖 ∗
𝐶𝑝𝑎𝑛 𝑔 − 𝑢𝑝𝑎𝑛 𝑔
(𝐸𝐶50𝑖 − 𝑢𝑝𝑎𝑛 𝑔) + (𝐶𝑝𝑎𝑛 𝑔 − 𝑢𝑝𝑎𝑛 𝑔)
𝐻(𝐶𝑝𝑎𝑛 𝑔) 
𝐼𝑝𝑎𝑛 𝑙 = 1 − 𝐸min 𝑝𝑎𝑛 𝑙 ∗
𝐶𝑝𝑎𝑛 𝑖 − 𝑚𝑝𝑎𝑛 𝑖
(𝐼𝐶50𝑙 − 𝑚𝑝𝑎𝑛 𝑖) + (𝐶𝑝𝑎𝑛 𝑖 − 𝑚𝑝𝑎𝑛 𝑖)
𝐻(𝐶𝑝𝑎𝑛 𝑖) 
𝑓𝑜𝑟𝑔 ℎ =
𝐸max ℎ ∗ 𝐶𝑜𝑟𝑔 ℎ 𝑑𝑖𝑓
(𝑘𝐷ℎ − 𝐶𝑜𝑟𝑔 ℎ 𝑏𝑎𝑠𝑒) + 𝐶 𝑜𝑟𝑔 ℎ 𝑑𝑖𝑓 
 
 
𝑦: Mass of a species 
𝑧𝑎 𝑐 𝑏 : a (Compartment) , b (In or Out of Compartment), c(Species) 
 g – glucose, l – glucagon, i – insulin, b – Aβ, bg – glycated Aβ 
𝑘𝑝𝑒𝑟 : Perfusion of leaked species from intestines to VAT 
𝑘𝑑𝑖𝑠: Glucose absorption rate from food into intestines 
𝑘𝑒𝑙𝑖: Elimination rate constant 
𝑘𝑙𝑖𝑣 𝑔𝑒𝑛: Glucose generation in liver due to glycogenolysis 
𝑘𝑖𝑛𝑠 𝑐𝑜𝑛𝑠 𝑔: Insulin mediated glucose elimination rate constant  
𝑘𝑔𝑒𝑛 𝑙: Glucagon generation rate from pancreas 
𝑘𝑔𝑒𝑛 𝑖: Insulin generation rate from pancreas 
𝑘𝑔𝑒𝑛 𝑏: Aβ generation rate 
𝑘𝑟𝑥𝑛: 2
nd order glycation reaction rate 
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𝐸𝑚𝑎𝑥: Maximum effect constant 
 
𝐻(𝐶): Step function of concentration parameter 
 𝐻(𝐶 > 𝐶𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑) = 1 
𝐻(𝐶 ≤ 𝐶𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑) = 0 
𝐶𝑑𝑖𝑓: Difference of concentration with baseline concentration in a compartment 








































Intestines 11.2 54600 11211 4875 
VAT 0.3 270 55 900 
Pancreas 1.11 7980 1639 7189 
Liver 25.1 88200 18111 3514 
Muscle 7.43 44940 9228 6048 

















System 84.9 1.53E-08 2.90E-05 1.39E-06 2.08E-09 
Intestines 84.9 1.53E-08 2.90E-05 1.39E-06 2.08E-09 
VAT 84.8 1.53E-08 2.90E-05 1.39E-06 2.09E-09 
Pancreas 84.9 1.55E-08 2.92E-05 1.40E-06 2.08E-09 
Liver 84.9 1.53E-08 2.90E-05 1.39E-06 2.08E-09 
Skeletal 
Muscle 84.9 1.53E-08 2.90E-05 1.39E-06 2.08E-09 






k eli g  1.7 
k eli l 1.5 
k eli i 10 
k eli b 123.15 
k eli bg 123.15 






k liv gen 7.36E+03 
k gen l 1.50E-06 











































Constants Values Units 
EC50i 300 mg/dL 
E max pan i 50 ~ 
IC50l 8.71E-04 mg/dL 
E min pan l 2 ~ 
E max cons 31 ~ 
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APPENDIX 3 MATLAB Code of Compartmental Model Script 
%{ 
This model accounts for insulin and glucagon in response to glucose changes 
in the blood to mediate a healthy glucose response in an adult 70kg male. 
Using the glucose concentrations in the compartments, we quantify its 






Volume Parameters for Concentrations 
V_vat_bl = 2.97 / 10 ; 
V_liv_bl = 25.1 ; 
V_mus_bl = 7.43 ; 
V_int_bl = 11.2 ; 
V_pan_bl = 15.8/100*70/10; 
V_cir = (50 - (V_vat_bl + V_liv_bl + V_mus_bl + V_int_bl + V_pan_bl)); 
V_arr = [V_cir V_int_bl V_vat_bl V_pan_bl V_liv_bl V_mus_bl]; 
Initial Values for each Species and Dose 
dose1 = 50000; 
dose2 = 5000; 
m_lvl_g = 85; 
m_lvl_i = 0.00002904; 
m_lvl_l = 1.532388 * (10 ^ (-8)); 
m_lvl_b = (14.33*(10^(-9))) / 0.01; 
m_lvl_bg = 0.03 * m_lvl_b; 
m_lvl_b = m_lvl_b * 0.97; 
48 
 
iv_1 = [ 
    m_lvl_g*V_cir;              %Glucose 
    m_lvl_g*V_int_bl; 
    m_lvl_g*V_vat_bl; 
    m_lvl_g*V_pan_bl; 
    m_lvl_g*V_liv_bl; 
    m_lvl_g*V_mus_bl; 
 
    m_lvl_l*V_cir;              %Glucagon 
    m_lvl_l*V_int_bl; 
    m_lvl_l*V_vat_bl; 
    m_lvl_l*V_pan_bl; 
    m_lvl_l*V_liv_bl; 
    m_lvl_l*V_mus_bl; 
 
    m_lvl_i*V_cir;              %Insulin 
    m_lvl_i*V_int_bl; 
    m_lvl_i*V_vat_bl; 
    m_lvl_i*V_pan_bl; 
    m_lvl_i*V_liv_bl; 
    m_lvl_i*V_mus_bl; 
 
    m_lvl_b*V_cir;              %Beta Amyloid 
    m_lvl_b*V_int_bl; 
    m_lvl_b*V_vat_bl; 
    m_lvl_b*V_pan_bl; 
    m_lvl_b*V_liv_bl; 




    m_lvl_bg*V_cir;              %Glycated Beta Amyloid 
    m_lvl_bg*V_int_bl; 
    m_lvl_bg*V_vat_bl; 
    m_lvl_bg*V_pan_bl; 
    m_lvl_bg*V_liv_bl; 
    m_lvl_bg*V_mus_bl; 
 
    0;           %Food 
    ]; 
ODE Solver 
t_ini = 0; 
t_fin = 5; 
tspan = t_ini:0.1:t_fin; 
[t, Ab] = ode15s(@ModelPB_G_I_L_BA, tspan, iv_1); %Sets up system 
t_stab = t; 
Ab_stab = Ab(end, :); 
 
initial_values = Ab_stab; 
init_vol_ar = initial_values(7:end); 
initial_values(end) = initial_values(end) + dose1; 
 
t_add = 4; 
t_end = t_fin + t_add; 
tspan = [t_fin t_end]; 
[t, Ab] = ode15s(@ModelPB_G_I_L_BA, tspan, initial_values); 
Ab = [Ab; Ab]; 





Ab_cir_g = Ab(:,1); 
Ab_int_g = Ab(:,2); 
Ab_vat_g = Ab(:,3); 
Ab_pan_g = Ab(:,4); 
Ab_liv_g = Ab(:,5); 
Ab_mus_g = Ab(:,6); 
Cp_cir_g = Ab_cir_g / V_cir; 
Cp_int_g = Ab_int_g / V_int_bl; 
Cp_vat_g = Ab_vat_g / V_vat_bl; 
Cp_pan_g = Ab_pan_g / V_pan_bl; 
Cp_liv_g = Ab_liv_g / V_liv_bl; 
Cp_mus_g = Ab_mus_g / V_mus_bl; 
 
%Glucagon 
Ab_cir_l = Ab(:,7); 
Ab_int_l = Ab(:,8); 
Ab_vat_l = Ab(:,9); 
Ab_pan_l = Ab(:,10); 
Ab_liv_l = Ab(:,11); 
Ab_mus_l = Ab(:,12); 
Cp_cir_l = Ab_cir_l / V_cir; 
Cp_int_l = Ab_int_l / V_int_bl; 
Cp_vat_l = Ab_vat_l / V_vat_bl; 
Cp_pan_l = Ab_pan_l / V_pan_bl; 
Cp_liv_l = Ab_liv_l / V_liv_bl; 
Cp_mus_l = Ab_mus_l / V_mus_bl; 
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Cp_cir_l_f = Ab_cir_l / init_vol_ar(1); 
Cp_int_l_f = Ab_int_l / init_vol_ar(2); 
Cp_vat_l_f = Ab_vat_l / init_vol_ar(3); 
Cp_pan_l_f = Ab_pan_l / init_vol_ar(4); 
Cp_liv_l_f = Ab_liv_l / init_vol_ar(5); 
Cp_mus_l_f = Ab_mus_l / init_vol_ar(6); 
 
%Insulin 
Ab_cir_i = Ab(:,13); 
Ab_int_i = Ab(:,14); 
Ab_vat_i = Ab(:,15); 
Ab_pan_i = Ab(:,16); 
Ab_liv_i = Ab(:,17); 
Ab_mus_i = Ab(:,18); 
Cp_cir_i = Ab_cir_i / V_cir; 
Cp_int_i = Ab_int_i / V_int_bl; 
Cp_vat_i = Ab_vat_i / V_vat_bl; 
Cp_pan_i = Ab_pan_i / V_pan_bl; 
Cp_liv_i = Ab_liv_i / V_liv_bl; 
Cp_mus_i = Ab_mus_i / V_mus_bl; 
Cp_cir_i_f = Ab_cir_i / init_vol_ar(7); 
Cp_int_i_f = Ab_int_i / init_vol_ar(8); 
Cp_vat_i_f = Ab_vat_i / init_vol_ar(9); 
Cp_pan_i_f = Ab_pan_i / init_vol_ar(10); 
Cp_liv_i_f = Ab_liv_i / init_vol_ar(11); 
Cp_mus_i_f = Ab_mus_i / init_vol_ar(12); 
 
%Beta Amyloid 1-42 Unglycated 
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Ab_cir_b = Ab(:,19); 
Ab_int_b = Ab(:,20); 
Ab_vat_b = Ab(:,21); 
Ab_pan_b = Ab(:,22); 
Ab_liv_b = Ab(:,23); 
Ab_mus_b = Ab(:,24); 
Cp_cir_b = Ab_cir_b / V_cir; 
Cp_int_b = Ab_int_b / V_int_bl; 
Cp_vat_b = Ab_vat_b / V_vat_bl; 
Cp_pan_b = Ab_pan_b / V_pan_bl; 
Cp_liv_b = Ab_liv_b / V_liv_bl; 
Cp_mus_b = Ab_mus_b / V_mus_bl; 
Cp_cir_b_f = Ab_cir_b / init_vol_ar(13); 
Cp_int_b_f = Ab_int_b / init_vol_ar(14); 
Cp_vat_b_f = Ab_vat_b / init_vol_ar(15); 
Cp_pan_b_f = Ab_pan_b / init_vol_ar(16); 
Cp_liv_b_f = Ab_liv_b / init_vol_ar(17); 
Cp_mus_b_f = Ab_mus_b / init_vol_ar(18); 
 
%Beta Amyloid 1-42 Glycated 
Ab_cir_bg = Ab(:,25); 
Ab_int_bg = Ab(:,26); 
Ab_vat_bg = Ab(:,27); 
Ab_pan_bg = Ab(:,28); 
Ab_liv_bg = Ab(:,29); 
Ab_mus_bg = Ab(:,30); 
Cp_cir_bg = Ab_cir_bg / V_cir; 
Cp_int_bg = Ab_int_bg / V_int_bl; 
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Cp_vat_bg = Ab_vat_bg / V_vat_bl; 
Cp_pan_bg = Ab_pan_bg / V_pan_bl; 
Cp_liv_bg = Ab_liv_bg / V_liv_bl; 
Cp_mus_bg = Ab_mus_bg / V_mus_bl; 
Cp_cir_bg_f = Ab_cir_bg / init_vol_ar(19); 
Cp_int_bg_f = Ab_int_bg / init_vol_ar(20); 
Cp_vat_bg_f = Ab_vat_bg / init_vol_ar(21); 
Cp_pan_bg_f = Ab_pan_bg / init_vol_ar(22); 
Cp_liv_bg_f = Ab_liv_bg / init_vol_ar(23); 







APPENDIX IV MATLAB Code of Compartmental Model ODE System 
%{ 
Glucose homeostasis multi compartment model ODE to quantify beta amyloid 
accumulation due to glucose concentrations in compartments 
%} 
 





Organ & Blood Flow Constants 
V_vat_bl = 2.97 / 10; 
V_liv_bl = 25.1; 
V_mus_bl = 7.43; 
V_int_bl = 11.2; 
V_pan_bl = 15.8/100*70/10; 
V_cir = (50 - (V_vat_bl + V_liv_bl + V_mus_bl + V_int_bl + V_pan_bl)); 
 
u_lvl_g = 110; 
if (t <= t_fin) 
    i_v = iv_1; 
else 
    i_v = Ab_stab(end, :); 
end 
 
Q_vat = 270; 
Q_mus = 749 * 60; 
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Q_int = 910 * 60; 
Q_pan = 133 * 60; 
Q_liv = 1470 * 60; 
Q_per = (185*1000./24)./(85*V_vat_bl); %Perfusion from Int to VAT 
 
k_per_o = Q_per ./ V_int_bl; 
k_int_o = Q_int ./ V_int_bl; 
k_vat_o = (Q_vat + Q_per) ./ V_vat_bl; 
k_pan_o = Q_pan ./ V_pan_bl; 
k_liv_o = (Q_liv + Q_int + Q_pan + Q_vat + Q_per) ./ V_liv_bl; 
k_mus_o = Q_mus ./ V_mus_bl; 
 
k_int_i = (Q_int + Q_per) ./ V_cir; 
k_vat_i = Q_vat ./ V_cir; 
k_liv_i = Q_liv ./ V_cir; 
k_mus_i = Q_mus ./ V_cir; 
k_pan_i = Q_pan ./ V_cir; 
Food Glucose Absorption/Elimination and Hormone Constants 
%Glucose Constants 
k_eli_g = 1.7; 
k_dis = 0.5; %Absorption Constant of glucose 
 
%Insulin Constants 
k_eli_i = 1.7; 
EC50_i = 300; %Response to generate insulin in pancreas %VC 
 
%Glucagon Constants 
k_eli_l = 3; 
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f_nM_mg_dL = 1 ./ (10^9) * 3482.7 * 1000 ./ 10; 
k_D_g_gen = 2.5*f_nM_mg_dL; %Response of glucagon on liver 
EC50_l = k_D_g_gen; %Response to generate glucagon in pancreas 
 
%Concentrations in compartments 
C_liv_l = y(11) ./ V_liv_bl; 
C_liv_l_c = i_v(11) ./ V_liv_bl; 
C_pan_i = y(16) ./ V_pan_bl; 
C_pan_g = y(4) ./ V_pan_bl; 
C_pan_i_c = i_v(16) ./ V_pan_bl; 
C_pan_g_du = C_pan_g - u_lvl_g; 
C_pan_i_dm = C_pan_i - C_pan_i_c; 
 
if (C_pan_g_du < 0) 
    C_pan_g_du = 0; 
end 
if (C_pan_i_dm < 0) 




E_max_pan_i = 50; 
E_min_pan_l = 2; 
I_pan_l = 1 - E_min_pan_l * C_pan_i_dm ./ ((EC50_l - C_pan_i_c) + C_pan_i_dm); 
I_pan_l_c = 1; 
hc = 1; 




dif_liv_l = abs(C_liv_l - C_liv_l_c); 
f_liv_l_c = 1; 
EC50_l_liv = C_liv_l_c * 10 - C_liv_l_c; 
if (C_liv_l >= C_liv_l_c) 
    f_liv_l = f_liv_l_c + dif_liv_l ./ (EC50_l_liv + dif_liv_l); 
else 
    f_liv_l = f_liv_l_c - dif_liv_l ./ (EC50_l_liv + dif_liv_l); 
end 
Insulin Enhanced glucose absorption 
C_mus_i = y(18) ./ V_mus_bl; 
C_mus_i_c = i_v(18) ./ V_mus_bl; 
C_vat_i = y(15) ./ V_vat_bl; 
C_vat_i_c = i_v(15) ./ V_vat_bl; 
C_liv_i = y(17) ./ V_liv_bl; 
C_liv_i_c = i_v(17) ./ V_liv_bl; 
 
%Insulin Consumption Effect 
k_ins_g_cons = 0.1; 
k_D_i_cons = (3.7 / (10^9) * 5734 / 10)*15; %Response to consume glucose from insulin 
E_max_cons = 31;%30; 
dif_mus = C_mus_i - C_mus_i_c; 
dif_vat = C_vat_i - C_vat_i_c; 
dif_liv = C_liv_i - C_liv_i_c; 
 
if (dif_mus < 0) 
    dif_mus = 0; 
end 
if (dif_vat < 0) 
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    dif_vat = 0; 
end 
if (dif_liv < 0) 
    dif_liv = 0; 
end 
 
hc_i = 1; 
f_mus_i_c = C_mus_i / (k_D_i_cons + C_mus_i); 
f_vat_i_c = C_vat_i / (k_D_i_cons + C_vat_i); 
f_liv_i_c = C_liv_i / (k_D_i_cons + C_liv_i); 
f_mus_i = f_mus_i_c + E_max_cons * (dif_mus^hc_i) ./ ((k_D_i_cons-C_mus_i_c)^hc_i + 
dif_mus^hc_i); 
f_vat_i = f_vat_i_c + E_max_cons * (dif_vat^hc_i) ./ ((k_D_i_cons-C_vat_i_c)^hc_i + 
dif_vat^hc_i); 
f_liv_i = f_liv_i_c + E_max_cons * (dif_liv^hc_i) ./ ((k_D_i_cons-C_liv_i_c)^hc_i + 
dif_liv^hc_i); 
Generation Constants 
k_liv_gen = (k_eli_g*sum(i_v(1:6)) + k_ins_g_cons*(f_vat_i_c*i_v(3) + f_liv_i_c*i_v(5) + 
f_mus_i_c*i_v(6))) ./ f_liv_l_c; 
k_gen_l = k_eli_l * (i_v(11) + i_v(12)) ./ I_pan_l_c; 
k_gen_i = k_eli_i * (i_v(15) + i_v(17) + i_v(18)); 
Beta Amyloid Protein Binding Elimination 
fac = 1.5; 
k_D_b = (6.95 * (10 ^(-6)) * 4514.04 ./ 10 * 1000); 
k_D_bg = k_D_b * fac; 
 
%Competitive Protein Binding with NEP betw Glycated and Non-Glycated BA 
C_cir_b = y(19) ./ V_cir; 
C_int_b = y(20) ./ V_int_bl; 
C_liv_b = y(23) ./ V_liv_bl; 
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C_cir_bg = y(25) ./ V_cir; 
C_int_bg = y(26) ./ V_int_bl; 
C_liv_bg = y(29) ./ V_liv_bl; 
 
f_cir_b = C_cir_b ./ (C_cir_b + k_D_b * (1 + (C_cir_bg ./ k_D_bg))); 
f_int_b = C_int_b ./ (C_int_b + k_D_b * (1 + (C_int_bg ./ k_D_bg))); 
f_liv_b = C_liv_b ./ (C_liv_b + k_D_b * (1 + (C_liv_bg ./ k_D_bg))); 
 
f_cir_bg = C_cir_bg ./ (C_cir_bg + k_D_bg * (1 + (C_cir_b ./ k_D_b))); 
f_int_bg = C_int_bg ./ (C_int_bg + k_D_bg * (1 + (C_int_b ./ k_D_b))); 
f_liv_bg = C_liv_bg ./ (C_liv_bg + k_D_bg * (1 + (C_liv_b ./ k_D_b))); 
 
i_cir_c = i_v(19) ./ V_cir; 
i_int_c = i_v(20) ./ V_int_bl; 
i_liv_c = i_v(23) ./ V_liv_bl; 
i_cir_cg = i_v(25) ./ V_cir; 
i_int_cg = i_v(26) ./ V_int_bl; 
i_liv_cg = i_v(29) ./ V_liv_bl; 
 
f_cir_c = i_cir_c ./ (i_cir_c + k_D_b * (1 + (i_cir_cg ./ k_D_bg))); 
f_int_c = i_int_c ./ (i_int_c + k_D_b * (1 + (i_int_cg ./ k_D_bg))); 
f_liv_c = i_liv_c ./ (i_liv_c + k_D_b * (1 + (i_liv_cg ./ k_D_bg))); 
 
k_eli_b = 123.15; 
k_eli_bg = k_eli_b; 
 
beta =  (i_v(1)*i_v(19)./V_cir + i_v(2)*i_v(20)./V_int_bl + i_v(3)*i_v(21)./V_vat_bl + 
i_v(4)*i_v(22)./V_pan_bl + i_v(5)*i_v(23)./V_liv_bl + i_v(6)*i_v(24)./V_mus_bl); 
krxn = 0.23 / 85 * 0.1; 
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k_gen_b = 0.5 * (k_eli_b * (f_cir_c + f_int_c + f_liv_c) + (krxn * beta)); 
Accumulation of Beta Amyloids in plasma 
Age - 34 -> 64 yrs plasma BA 1-42 - 14.33 -> 18.54 frac change (a) - (18.54 - 14.33) / 14.33 
slope - (a)/(64-34)/365 (frac change / days) slope - (a)/(64-34)/365/24 (frac change / hrs) 
if (t > t_fin) 
    frac_change = (18.54 - 14.33) / 14.33; 
    rate_accum = frac_change / (30 * 365 * 24); 
    rate_degrd = 1 - rate_accum * t*0.78888888; 
    k_eli_b = k_eli_b * rate_degrd; 
    k_eli_bg = k_eli_b; 
end 
Collapsed Constants 
k_cir_o = k_int_i + k_vat_i + k_liv_i + k_mus_i + k_pan_i; 
k_liv_g_i_tot = (k_liv_i * y(1)) + (k_int_o * y(2)) + (k_vat_o * y(3)) + (k_pan_o * y(4)); 
k_liv_l_i_tot = (k_liv_i * y(7)) + (k_int_o * y(8)) + (k_vat_o * y(9)) + (k_pan_o * y(10)); 
k_liv_i_i_tot = (k_liv_i * y(13)) + (k_int_o * y(14)) + (k_vat_o * y(15)) + (k_pan_o * y(16)); 
k_liv_b_i_tot = (k_liv_i * y(19)) + (k_int_o * y(20)) + (k_vat_o * y(21)) + (k_pan_o * y(22)); 
k_liv_bg_i_tot = (k_liv_i * y(25)) + (k_int_o * y(26)) + (k_vat_o * y(27)) + (k_pan_o * y(28)); 
SOE 
dydt = [ 
 
    %GLUCOSE - Blood 
    %1-Circulatory Blood 
    -k_cir_o * y(1) + k_liv_o * y(5) + k_mus_o * y(6) - k_eli_g * y(1); 
    %2-Intestines 
    k_int_i * y(1) - (k_int_o + k_per_o) * y(2) - k_eli_g * y(2) + k_dis * y(end); 
    %3-Visceral Adipose Tissue (VAT) 




    %4-Pancreas 
    k_pan_i * y(1) - k_pan_o * y(4) - k_eli_g * y(4); 
    %5-Liver 
    k_liv_g_i_tot - k_liv_o * y(5) - k_eli_g * y(5) + f_liv_l*k_liv_gen - k_ins_g_cons * f_liv_i * 
y(5); 
    %6-Muscle 
    k_mus_i * y(1) - k_mus_o * y(6) - k_eli_g * y(6) - k_ins_g_cons * f_mus_i * y(6); 
 
    %GLUCAGON 
    %7-Circulatory Blood 
    -k_cir_o * y(7) + k_liv_o * y(11) + k_mus_o * y(12); 
    %8-Intestines 
    k_int_i * y(7) - (k_int_o) * y(8) - k_per_o * y(8); 
    %9-Visceral Adipose Tissue (VAT) 
    k_vat_i * y(7) - (k_vat_o) * y(9) + k_per_o * y(8); 
    %10-Pancreas 
    k_pan_i * y(7) - (k_pan_o) * y(10) + k_gen_l * I_pan_l; 
    %11-Liver 
    k_liv_l_i_tot  - k_liv_o * y(11) - k_eli_l * y(11); 
    %12-Muscle 
    k_mus_i * y(7) - (k_mus_o + k_eli_l) * y(12); 
 
    %INSULIN 
    %13-Circulatory Blood 
    -k_cir_o * y(13) + k_liv_o * y(17) + k_mus_o * y(18); 
    %14-Intestines 
    k_int_i * y(13) - (k_int_o) * y(14) - k_per_o * y(14); 
    %15-Visceral Adipose Tissue (VAT) 
    k_vat_i * y(13) - (k_vat_o + k_eli_i) * y(15) + k_per_o * y(14); 
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    %16-Pancreas 
    k_pan_i * y(13) - (k_pan_o) * y(16) + k_gen_i * S_pan_i; 
    %17-Liver 
    k_liv_i_i_tot - (k_liv_o + k_eli_i) * y(17); 
    %18-Muscle 
    k_mus_i * y(13) - (k_mus_o + k_eli_i) * y(18); 
 
    %BETA AMYLOID 
    %19-Circulatory Blood 
    -k_cir_o * y(19) + k_liv_o * y(23) + k_mus_o * y(24) - k_eli_b * f_cir_b + k_gen_b - krxn * 
y(1) * y(19) / (V_cir^1); 
    %20-Intestines 
    k_int_i * y(19) - (k_int_o + k_per_o) * y(20) - k_eli_b * f_int_b + k_gen_b/2 - krxn * y(2) * 
y(20) / (V_int_bl^1); 
    %21-Visceral Adipose Tissue (VAT) 
    k_vat_i * y(19) + k_per_o * y(20) - k_vat_o * y(21) - krxn *  y(3) * y(21) / (V_vat_bl^1); 
    %22-Pancreas 
    k_pan_i * y(19) - k_pan_o * y(22) + k_gen_b/2 - krxn * y(4) * y(22) / (V_pan_bl^1); 
    %23-Liver 
    k_liv_b_i_tot - k_liv_o * y(23) - k_eli_b * f_liv_b - krxn * y(5) * y(23) / (V_liv_bl^1); 
    %24-Muscle 
    k_mus_i * y(19) - k_mus_o * y(24) - krxn * y(6) * y(24) / (V_mus_bl^1); 
 
    %GLYCATED - BETA AMYLOID 
    %25-Circulatory Blood 
    -k_cir_o * y(25) + k_liv_o * y(29) + k_mus_o * y(30) - k_eli_bg * f_cir_bg + krxn * y(1) * 
y(19) / (V_cir^1); 
    %26-Intestines 




    %27-Visceral Adipose Tissue (VAT) 
    k_vat_i * y(25) + k_per_o * y(26) - k_vat_o * y(27)  + krxn * y(3) * y(21) / (V_vat_bl^1); 
    %28-Pancreas 
    k_pan_i * y(25) - k_pan_o * y(28) + krxn * y(4) * y(22) / (V_pan_bl^1); 
    %29-Liver 
    k_liv_bg_i_tot - k_liv_o * y(29) - k_eli_bg * f_liv_bg + krxn * y(5) * y(23) / (V_liv_bl^1); 
    %30-Muscle 
    k_mus_i * y(25) - k_mus_o * y(30) + krxn * y(6) * y(24) / (V_mus_bl^1); 
 
    %31-Food 
    (-k_dis * y(end)); 




APPENDIX V MATLAB Code for Repeated Meals w/ Variable Factor 
dose = 50000; 
 
V_vat_bl = 2.97 / 10 ; 
V_liv_bl = 25.1 ; 
V_mus_bl = 7.43 ; 
V_int_bl = 11.2 ; 
V_pan_bl = 15.8/100*70/10; 
V_cir = (50 - (V_vat_bl + V_liv_bl + V_mus_bl + V_int_bl + V_pan_bl)); 
V_arr = [V_cir V_int_bl V_vat_bl V_pan_bl V_liv_bl V_mus_bl]; 
 
m_lvl_g = 85; 
m_lvl_i = 0.00002904; 
m_lvl_l = 1.532388 * (10 ^ (-8)); 
m_lvl_b = (14.33*(10^(-9))) / 0.01; 
m_lvl_bg = 0.03 * m_lvl_b; 
m_lvl_b = m_lvl_b * 0.97; 
iv_1 = [ 
    m_lvl_g*V_cir;              %Glucose 
    m_lvl_g*V_int_bl; 
    m_lvl_g*V_vat_bl; 
    m_lvl_g*V_pan_bl; 
    m_lvl_g*V_liv_bl; 
    m_lvl_g*V_mus_bl; 
 
    m_lvl_l*V_cir;              %Glucagon 
    m_lvl_l*V_int_bl; 
    m_lvl_l*V_vat_bl; 
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    m_lvl_l*V_pan_bl; 
    m_lvl_l*V_liv_bl; 
    m_lvl_l*V_mus_bl; 
 
    m_lvl_i*V_cir;              %Insulin 
    m_lvl_i*V_int_bl; 
    m_lvl_i*V_vat_bl; 
    m_lvl_i*V_pan_bl; 
    m_lvl_i*V_liv_bl; 
    m_lvl_i*V_mus_bl; 
 
    m_lvl_b*V_cir;              %Beta Amyloid 
    m_lvl_b*V_int_bl; 
    m_lvl_b*V_vat_bl; 
    m_lvl_b*V_pan_bl; 
    m_lvl_b*V_liv_bl; 
    m_lvl_b*V_mus_bl; 
 
    m_lvl_bg*V_cir;              %Glycated Beta Amyloid 
    m_lvl_bg*V_int_bl; 
    m_lvl_bg*V_vat_bl; 
    m_lvl_bg*V_pan_bl; 
    m_lvl_bg*V_liv_bl; 
    m_lvl_bg*V_mus_bl; 
 
    0;           %Food 








ba_bag_range = 19:(length(iv_1)-1); 
reset_ba_bag = iv_1(ba_bag_range); 
 
k_fac_var = [0.1 0.2 0.5 1 2 5 10]; 
k1 = 0; 
k2 = 0; 
k3 = 0; 
k4 = 0; 
k5 = 0; 
k6 = 0; 
k7 = 0; 
t1 = 0; 
t2 = 0; 
t3 = 0; 
t4 = 0; 
t5 = 0; 
t6 = 0; 
t7 = 0; 
 
 
for rp_fac = 1:length(k_fac_var) 
    k_fac = k_fac_var(rp_fac); 
    t_ini = 0; 
    t_fin = 5; 
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    tspan = t_ini:0.1:t_fin; 
    [t, Ab] = ode15s(@ModelPB_G_I_L_BA_RM, tspan, iv_1); 
    t_stab = t; 
    Ab_stab = Ab(end, :); 
    t_set = t_fin; 
    iv_set = Ab_stab; 
    b_range = 19:30; 
    tot_days = 30*365; 
    Ab_days = NaN((tot_days+1), length(b_range)); 
    Ab_days(1, :) = Ab(end, b_range); 
    t_days = 1:length(tot_days+1); 
    t_days(1) = t(end) - t_fin; 
 
    for rep = 1:tot_days 
        if (rep > 1) 
            initial_values = Ab_dinner(end, :)'; 
            initial_values(end) = initial_values(end) + dose; 
            t_set = t_end; 
        else 
            initial_values = iv_set; 
            initial_values(end) = initial_values(end) + dose; 
        end 
 
        t_add_break = 4; 
        t_end = t_set + t_add_break; 
        tspan = [t_set t_end]; 
        [t_break, Ab_break] = ode15s(@ModelPB_G_I_L_BA_RM, tspan, initial_values); 
%         Ab = [Ab; Ab_break]; 
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%         t = [t; t_break]; 
 
        initial_values = Ab_break(end, :)'; 
        initial_values(end) = initial_values(end) + dose; 
        t_add_lunch = 8; 
        t_set = t_end; 
        t_end = t_set + t_add_lunch; 
        tspan = [t_set t_end]; 
        [t_lunch, Ab_lunch] = ode15s(@ModelPB_G_I_L_BA_RM, tspan, initial_values); 
%         Ab = [Ab; Ab_lunch]; 
%         t = [t; t_lunch]; 
 
        initial_values = Ab_lunch(end, :)'; 
        initial_values(end) = initial_values(end) + dose; 
        t_add_dinner = 12; 
        t_set = t_end; 
        t_end = t_set + t_add_dinner; 
        tspan = [t_set t_end]; 
        [t_dinner, Ab_dinner] = ode15s(@ModelPB_G_I_L_BA_RM, tspan, initial_values); 
%         Ab = [Ab; Ab_dinner]; 
%         t = [t; t_dinner]; 
        Ab_days((rep+1),:) = Ab_dinner(end, b_range); 
        t_days(rep+1) = t_dinner(end); 
 
    end 
    if (rp_fac == 1) 
        k1 = Ab_days; 
        t1 = t_days; 
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    elseif (rp_fac == 2) 
        k2 = Ab_days; 
        t2 = t_days; 
    elseif (rp_fac == 3) 
        k3 = Ab_days; 
        t3 = t_days; 
    elseif (rp_fac == 4) 
        k4 = Ab_days; 
        t4 = t_days; 
    elseif (rp_fac == 5) 
        k5 = Ab_days; 
        t5 = t_days; 
    elseif (rp_fac == 6) 
        k6 = Ab_days; 
        t6 = t_days; 
    elseif (rp_fac == 7) 
        k7 = Ab_days; 
        t7 = t_days; 
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